Adverse Events Reporting in Oncology Studies Suboptimal

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology - FDA Approvals

Transparent and comprehensive reporting of adverse events (AEs) in published results of oncology-related clinical trials is crucial for the treatment of patients with cancer. The Consolidated Standards of Reporting Trials (CONSORT) extension group had developed 10 recommendations in 2003 for reporting AEs. A new analysis of 175 publications recently assessed the degree to which the publication of phase 3 trial results in oncology adhered with CONSORT recommendations (Sivendran S, et al. J Clin Oncol. 2014;32:83-89).

Based on this analysis, the published reports of AEs is suboptimal and is characterized by significant selectivity of the data. The analysis involved randomized, phase 3 clinical trials in metastatic solid malignancies published between January 2009 and December 2011. Publications were assessed for 14 AEs listed in the CONSORT harms extension statement, using a completeness score of 0 to 14.

Data on 96,125 patients were included. The median completeness score was 8. The majority of publications (96%) only reported AEs above a particular threshold rate or severity. Overall, 37% did not specify the criteria used to report AEs, and 88% grouped AEs of varying severity.

Only 77% of articles reported absolute numbers of AEs, 75% reported if there were deaths related to AEs, 71% reported whether patients were evaluable for toxicity, and 65% reported reasons for treatment discontinuation.

In addition, trials without a specified funding source were associated with significantly lower AE complete reporting scores.

This analysis shows substantial selectivity in the reporting of AEs in oncology publications.

Related Items
FDA Approves Darzalex Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma
Web Exclusives published on September 27, 2019 in FDA Approvals, Multiple Myeloma, In the News
Polivy FDA Approved for Patients with Relapsed or Refractory DLBCL
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in FDA Approvals
Xpovio Receives FDA Approval for Patients with Relapsed or Refractory Multiple Myeloma
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in FDA Approvals
Revlimid Approved for Patients with Follicular Lymphoma or Marginal-Zone Lymphoma
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in FDA Approvals
Keytruda First PD-1 Inhibitor Approved as First-Line Monotherapy for Patients with Metastatic or Unresectable Head and Neck Cancer
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in FDA Approvals
Last modified: March 4, 2014
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME